<DOC>
	<DOCNO>NCT01677390</DOCNO>
	<brief_summary>This phase 1 , open-label , dose-escalation clinical trial evaluate safety SGN-75 combination everolimus patient CD70-positive metastatic renal cell carcinoma .</brief_summary>
	<brief_title>A Phase 1b Study SGN-75 Combination With Everolimus Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diagnosis metastatic renal cell carcinoma confirm CD70 expression Previously treat least 1 tyrosine kinase inhibitor ( TKI ) Measurable disease Eastern Cooperative Oncology Group performance status 0 1 Adequate lung renal function Prior treatment antiCD70directed therapy Received one prior treatment mTOR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>monomethylauristatin F</keyword>
	<keyword>Carcinoma , Renal Cell</keyword>
	<keyword>Antigens , CD70</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>